Abstract
In many countries, hormone receptor status assessment of ductal carcinoma in situ (DCIS) is routinely performed, as hormone receptor-positive DCIS patients are eligible for adjuvant anti-hormonal treatment, aiming to reduce the ipsilateral and contralateral breast cancer risk. Although HER2 gene amplification and its associated HER2 protein overexpression constitute a major prognostic and predictive marker in invasive breast carcinoma, its use in the diagnosis and treatment of DCIS is less straightforward. HER2 immunohistochemistry is not routinely performed yet, as the role of HER2-positivity in DCIS biology is unclear. Nonetheless, recent data challenge this practice. Here, we discuss the value of routine HER2 assessment for DCIS. HER2-positivity correlates strongly with DCIS grade: around four in five HER2-positive DCIS show high grade atypia. As morphological DCIS grading is prone to interobserver variability, HER2 immunohistochemistry could render grading more robust. Several studies showed an association between HER2-positive DCIS and ipsilateral recurrence risk, albeit currently unclear whether this is for overall, in situ or invasive recurrence. HER2-positive DCIS tends to be larger, with a higher risk of involved surgical margins. HER2-positive DCIS patients benefit more from adjuvant radiotherapy: it substantially decreases the local recurrence risk after lumpectomy, without impact on overall survival. HER2-positivity in pure biopsy-diagnosed DCIS is associated with increased upstaging to invasive carcinoma after surgery. HER2 immunohistochemistry on preoperative biopsies might therefore provide useful information to surgeons, favoring wider excisions. The time seems right to consider DCIS subtype-dependent treatment, comprising appropriate local treatment for HER2-positive DCIS patients and de-escalation for hormone receptor-positive, HER2-negative DCIS patients.
Original language | English |
---|---|
Article number | 125 |
Journal | Breast Cancer Research |
Volume | 26 |
Issue number | 1 |
DOIs | |
Publication status | Published - 27 Aug 2024 |
Keywords
- Biopsy
- Breast
- Ductal carcinoma in situ
- Grade
- HER2
- Hormone receptor status
- Immunohistochemistry
- Nuclear atypia
- Personalized therapy
- Humans
- Receptor, ErbB-2/metabolism genetics
- Female
- Breast Neoplasms/pathology metabolism genetics therapy mortality diagnosis
- Carcinoma, Intraductal, Noninfiltrating/pathology therapy metabolism genetics
- Biomarkers, Tumor/metabolism
- Prognosis
- Neoplasm Recurrence, Local/metabolism pathology genetics
- Neoplasm Grading
- Clinical Relevance